Marina V. Taranova

Marina V. Taranova

Auto-generated profile, based on publicly available information

Marina V. Taranova

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2022 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
PDF file
LMLudmila Yu. Milovanova
Ludmila Yu. Milovanova
AVAlexey V. Volkov
Alexey V. Volkov
SMSvetlana Yu. Milovanova
Svetlana Yu. Milovanova
MTMarina V. Taranova
Marina V. Taranova
KNKirill S. Nezhdanov
Kirill S. Nezhdanov

9 July 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LMLudmila Yu. Milovanova
Ludmila Yu. Milovanova
L(Lidia V. Lysenko (Kozlovskaya)
Lidia V. Lysenko (Kozlovskaya)
SMSvetlana Yu. Milovanova
Svetlana Yu. Milovanova
MTMarina V. Taranova
Marina V. Taranova
VKVasiliy V. Kozlov
Vasiliy V. Kozlov
NCNatalia V. Chebotareva
Natalia V. Chebotareva
Cardiovascular calcification (CVC) makes a significant contribution to the manifestation of cardiovascular complications in patients with chronic kidney disease. Early CVC markers are currently being actively studied to optimize cardio-renoprotective strategies. We performed a prospective comparative analysis of the following factors: FGF-23, a-Klotho, sclecrostin, phosphate, parathyroid hormone, the estimated glomerular filtration rate (eGFR), central systolic pressure as an independent determinant of CVC. Materials and methods. The study included 131 patients with chronic kidney disease 25D st. Serum levels of FGF-23, Klotho, and sclerostin were evaluated using the ELISA method. Vascular augmentation (stiffness) indices, central arterial pressure (using the SphygmoCor device), calcification of heart valves and the degree of aortic calcification (aortic radiography) were also investigated. The observation period was 2 years. Results. According to the Spearman correlation analysis, the percent of calcification increase and the change in Klotho level are most related. According to ROC analysis, a decrease in serum levels of Klotho by 50 units or more is a significant predictor of an increase in aortic calcification of 50% or more with a sensitivity of 86% and a specificity of 77%. Using logistic regression analysis, it was found that a serum Klotho level 632 pg/L predicts an eGFR below a median level of 48 ml/min/1.73 m2 with a sensitivity of 85.5% and a specificity of 78.5%. Wherein OR 17.477 (CI 95% 8.04637.962; p0.001). Conclusion. The factor most associated with CVC is Klotho. Decreased serum level of Klotho is a predictor of aortic calcification. In addition, the initial serum level of Klotho is a predictor of eGFR after 2 years.

15 June 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LMLudmila Yu. Milovanova
Ludmila Yu. Milovanova
VBVladimir D. Beketov
Vladimir D. Beketov
SMSvetlana Yu. Milovanova
Svetlana Yu. Milovanova
MTMarina V. Taranova
Marina V. Taranova
VKVasilii V. Kozlov
Vasilii V. Kozlov
MKMikhail V. Kalashnikov
Mikhail V. Kalashnikov
Background. High risk of cardiovascular events is among leading problems in chronic kidney disease (CKD). Serum Klotho is supposed to be cardio- and nephroprotective; modification of its levels may be important in CKD. Aim. To evaluate the impact of vitamin D receptor activators (VDRA) on Klotho serum levels in CKD 3b4 stages patients. Materials and methods. Study included 90 CKD 3b4 stages patients who had elevated serum levels of parathyroid hormone (PTH). From them, 47 patients (group 1) started to treat with the selective VDRA (zemplar 1 mcg/day), and 43 patients (group 2) started to treat with non-selective VDRA (alfacalcidol 0.25 mcg/day). At baseline and after 12 months we conducted routine examination, serum Klotho measurement, and broad cardiovascular examination. Results. The patients who managed to maintain a target serum PTH level, had higher Klotho serum level (p=0.037) at the end of the study. Patients who used selective VDRA significantly more often reached the target PTH level (p=0.032), had higher serum Klotho levels (p=0.037), and glomerular filtration rate (eGFR) level (p=0.048) than patients who used non-selective VDRA. In addition, patients treated with alfacalcidol more than 6 months, more often had hypercalcemia (p=0.047) and hyperphosphatemia (p=0.035). Group 2 showed higher: pulse wave velocity (p=0.051), left ventricular myocardial mass index (p=0.033), and more advanced heart valve calcification (p=0.038). Conclusion. Successful parathyroid hormone level control with vitamin D receptor activators was associated with higher serum Klotho, selective agents having shown greater effect. Long-term treatment with selective vitamin D receptor activators may contribute to cardiovascular calcification prevention by modifying Klotho levels.

1 January 2017 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
YMYu. S. Milovanov
Yu. S. Milovanov
LKL. V. Kozlovskaya
L. V. Kozlovskaya
LML. Yu. Milovanova
L. Yu. Milovanova
MMM. M. Markina
M. M. Markina
VKV. V. Kozlov
V. V. Kozlov
VFV. V. Fomin
V. V. Fomin
To identify the early markers of anemia in chronic kidney disease (CKD) in patients with chronic glomerulonephritis (CGN) and glomerulonephritis (GN) in systemic diseases. Seventy-nine patients with some male preponderance who were aged 21 to 65 years (45.3±11.1 years) and had CKD (CGN and GN) in systemic diseases (systemic lupus erythematosus and Wegener's granulomatosis) in the early stages (Stages I-II) of CKD were examined. GN was diagnosed by a lifetime renal biopsy. Systemic diseases were diagnosed according to the criteria for each nosological entity. The stages of CKD were defined according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria; the glomerular filtration rate (GFR) was calculated using the CKD EPI equation (2012). According to the presence or absence of anemia, all the patients included in the study were divided into 2 groups: 1) 43 (54.4%) anemic patients; 2) 36 (45.6%) non-anemic patients (a control group). In addition to general clinical examination adopted for a nephrology department, special studies, such as determination of the serum levels of hepcidin, interferon-γ (IFN-γ), soluble Klotho protein (s-Klotho), as well as iron, ferritin, and transferrin saturation (TSAT) ratio, were performed to solve the set tasks. Forty-three anemic patients who had a hemoglobin level of 110 (100; 119) g/l and 36 control patients who had the similar values were noted to have statistically significantly (p 0.001), was associated with the development of anemia. Moreover, the hemoglobin level of<120 g/ l was found to have an independent impact on the risk of reducing serum s-Klotho production. In Stage I-II CKD patients with CGN and GN in the presence of systemic diseases, elevated serum hepcidin levels should be regarded as a predictor for anemia of chronic disease (ACD). Herewith, the decrease in hemoglobin levels <120 g/l is associated with the reduced production of the nephroprotective factor s-Klotho. The treatment of ACD for Stages I-II CKD should encompass intravenous administration of iron in order to increase its content and availability for erythropoiesis.

20 September 2021 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Closed access
PDF file
LML. Yu. Milovanova
L. Yu. Milovanova
VBV. D. Beketov
V. D. Beketov
SMS. Yu. Milovanova
S. Yu. Milovanova
MTM. V. Taranova
M. V. Taranova
AFA. A. Filippova
A. A. Filippova
APA. I. Pasechnik
A. I. Pasechnik
Сardiovascular disease (СVD) is the most common complication of chronic kidney disease (СKD). In patients with the earlier stages of CKD, the risk of death from CVD greatly exceeds the risk of progression to end-stage renal disease. In recent years, accumulated data suggest that chronic kidney disease — mineral and bone disorders (CKD-MBD) are strongly associated with cardiovascular events and mortality. Among cardiovascular damage in CKD, both, the progressive cardiac remodeling and vascular calcifi cation, contribute immensely, and lead to an urgently high cardiovascular mortality in patients with CKD. Clarifi cation of CKD progression mechanisms and possible early markers of CVD has led to interest in studying the identifi ed factors such as fi broblast growth factor-23 (FGF-23), Klotho and sclerostin in recent years. Results of studies show that disorders in the system of FGF-23–Klotho–sclerostin correlate with the frequency and severity of hypertension, cardiac remodeling, vascular calcifi cation, anaemia, malnutrition, infl ammation, and strongly aggravate cardiovascular risk in CKD. This review represents an analysis of the available data showing the potential association of СVD with established (phosphate, parathyroid hormone (PTH), Vitamin D) and newer (FGF-23, Klotho, sclerostin) СKD-MBD biomarkers. In addition, it has been shown that renoprotective therapy, including renin-angiotensin blockers, low-protein diet with amino/keto acid supplementation, phosphate binders, erythropoiesis stimulators, vitamin D metabolites used to reach the target levels of blood pressure, serum phosphorus, haemoglobin, PTH and nutritional status disorders, can aff ect CKD-MBD biomarkers and reduce the risk of cardiovascular events in CKD patients.

19 September 2016
Verified
Journal Article
Closed access
ЛМЛ.ю. Милованова
Л.ю. Милованова
ЛКЛ.в. Козловская
Л.в. Козловская
ГКГ.г. Киякбаев
Г.г. Киякбаев
ЮМЮ.с. Милованов
Ю.с. Милованов
МТМ.в. Таранова
М.в. Таранова
ОДО.с. Деревягина
О.с. Деревягина